Dr. Madigan has a strong scientific background and over 20 years of experience in corporate financing, operations, business development and M&A. He has been a founder and senior manager of six independent biotechnology companies for Avalon Ventures and four companies for Avalon X and XI under the Accelerator umbrella. Sandy is currently serving as CEO of four Avalon Ventures portfolio companies: Sova Pharmaceuticals, Anexigen, Inc., Ankasa Regenerative Therapeutics, and Nerio Therapeutics, Inc. Sandy has raised over $25M for Ankasa and was the transacting CEO of Calporta Therapeutics which was acquired by Merck in November, 2019 for up to $576M.
Dr. Madigan was also a founding member of various Avalon Ventures portfolio companies from earlier funds, including: Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen) and X-Ceptor Therapeutics (acquired by Exelixis). Outside of his roles in Avalon Ventures companies, Dr. Madigan served in various other venture-backed and non-venture financed biotechnology companies.
He was a founder and the CEO of Strategic Enzyme Applications, a private company established in partnership with Monsanto. Dr. Madigan was also a founder and VP Corporate Development for BioVerdant, a venture-backed clean technology company. In earlier roles, Dr. Madigan was a senior manager at Nereus Pharmaceuticals and SIBIA Neurosciences (acquired by Merck).
Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies. He received his Ph.D. in Genetics and his B.S. in Biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.